|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Thioacetamide results in increased expression of ACTA2 mRNA] |
CTD |
PMID:36343683 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Corticosterone results in decreased expression of ADORA1 mRNA] |
CTD |
PMID:31344373 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Lipopolysaccharides results in decreased expression of AGTR1A mRNA] |
CTD |
PMID:19118600 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of AGTR2 mRNA] |
CTD |
PMID:19118600 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 mRNA]; Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 protein] |
CTD |
PMID:18078833 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
Edaravone inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; Edaravone inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein] |
CTD |
PMID:18951527 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Edaravone inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; Edaravone inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; Edaravone inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Edaravone inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Edaravone inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of CASP12 protein] |
CTD |
PMID:21429313 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP ISO |
Edaravone inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; Edaravone inhibits the reaction [PRNP protein alternative form results in increased activity of CASP3 protein] Edaravone analog results in increased activity of CASP3 protein |
CTD |
PMID:20806394 PMID:25684395 PMID:25947082 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Edaravone analog results in increased activity of CASP7 protein |
CTD |
PMID:25684395 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
EXP |
Edaravone results in decreased expression of CASP8 protein |
CTD |
PMID:17967739 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Edaravone analog results in increased activity of CASP9 protein |
CTD |
PMID:25684395 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Iron-Dextran Complex results in decreased activity of CAT protein] |
CTD |
PMID:32135237 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL12 mRNA] |
CTD |
PMID:12954792 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
EXP ISO |
Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL2 mRNA]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased secretion of CCL2 protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of CCL2 protein] Edaravone inhibits the reaction [Thioacetamide results in increased expression of CCL2 mRNA] Edaravone results in decreased expression of CCL2 mRNA; Edaravone results in decreased expression of CCL2 protein |
CTD |
PMID:12954792 PMID:15948865 PMID:18803305 PMID:19381132 PMID:36343683 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
EXP |
Edaravone results in decreased expression of CCL3 mRNA |
CTD |
PMID:15948865 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Thioacetamide results in increased expression of CCR2 mRNA] |
CTD |
PMID:36343683 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Thioacetamide results in increased expression of COL1A1 mRNA] |
CTD |
PMID:36343683 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Corticosterone results in decreased expression of COMT mRNA] |
CTD |
PMID:31344373 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression multiple interactions |
EXP |
Edaravone results in decreased expression of CXCL1 mRNA; Edaravone results in decreased expression of CXCL1 protein Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] |
CTD |
PMID:14654979 PMID:15629513 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased secretion of CXCL12 protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of CXCL12 protein] |
CTD |
PMID:18803305 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression multiple interactions |
EXP |
Edaravone results in decreased expression of CXCL2 mRNA Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL2 mRNA] |
CTD |
PMID:12954792 PMID:15948865 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
EXP |
Edaravone results in decreased expression of CXCL3 mRNA |
CTD |
PMID:15948865 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Edaravone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA] |
CTD |
PMID:18643790 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Edaravone inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
EXP |
Edaravone results in decreased expression of DAXX mRNA; Edaravone results in decreased expression of DAXX protein |
CTD |
PMID:17967739 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Cisplatin results in decreased expression of EPHX2 protein] |
CTD |
PMID:26165641 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression |
EXP |
Edaravone results in increased expression of ERN1 mRNA |
CTD |
PMID:19558813 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Valproic Acid results in decreased activity of F3 protein] |
CTD |
PMID:25304967 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression |
EXP |
Edaravone results in decreased expression of FADD mRNA; Edaravone results in decreased expression of FADD protein |
CTD |
PMID:17967739 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Corticosterone results in decreased expression of FKBP5 mRNA] |
CTD |
PMID:31344373 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [cobaltous chloride results in increased expression of FLT1 mRNA]; Edaravone inhibits the reaction [cobaltous chloride results in increased expression of FLT1 protein] |
CTD |
PMID:24840734 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[Edaravone inhibits the reaction [HIF1A protein binds to VEGFA promoter]] which affects the expression of VEGFA mRNA; Edaravone inhibits the reaction [HIF1A protein binds to VEGFA promoter]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] |
CTD |
PMID:17889387 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Edaravone results in increased expression of HMOX1 mRNA; Edaravone results in increased expression of HMOX1 protein Edaravone promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein] |
CTD |
PMID:25348283 PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
EXP |
Edaravone results in decreased expression of HSPA1A mRNA; Edaravone results in decreased expression of HSPA1A protein |
CTD |
PMID:19338546 PMID:19694712 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Edaravone promotes the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of HSPA5 protein] |
CTD |
PMID:21429313 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Edaravone results in decreased expression of ICAM1 mRNA; Edaravone results in decreased expression of ICAM1 protein alternative form |
CTD |
PMID:15948865 PMID:16301206 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNG mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:12954792 PMID:15629513 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Carbon Tetrachloride results in increased expression of IL10 mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL10 mRNA] |
CTD |
PMID:12954792 PMID:14567445 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Thioacetamide results in increased expression of IL1A mRNA] |
CTD |
PMID:36343683 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of IL1B mRNA]; Edaravone inhibits the reaction [[Pilocarpine co-treated with Lithium] results in increased expression of IL1B protein]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Edaravone inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] Edaravone results in decreased expression of IL1B mRNA Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 mRNA]; Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 protein]; Edaravone inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Edaravone inhibits the reaction [IL1B protein results in increased localization of and results in increased activity of RELA protein]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased secretion of IL1B protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of IL1B protein] Edaravone results in decreased activity of IL1B protein |
CTD |
PMID:15629513 PMID:15948865 PMID:16390820 PMID:18078833 PMID:18803305 PMID:19951488 PMID:36343683 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 mRNA]; Edaravone inhibits the reaction [[IL1B protein results in increased phosphorylation of AKT1 protein] which results in increased expression of IL1R1 protein] |
CTD |
PMID:18078833 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Carbon Tetrachloride results in increased expression of IL4 mRNA] |
CTD |
PMID:14567445 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects activity decreases expression multiple interactions |
EXP |
Edaravone affects the activity of IL6 protein Edaravone results in decreased expression of IL6 mRNA Edaravone inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]; Edaravone inhibits the reaction [Paraquat results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:12954792 PMID:14567445 PMID:15629865 PMID:18031376 PMID:20035747 PMID:21040696 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Streptozocin results in decreased secretion of INS1 protein] |
CTD |
PMID:18291360 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases activity |
ISO |
Edaravone results in decreased activity of MAP3K5 protein |
CTD |
PMID:15824197 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation decreases phosphorylation |
ISO |
Edaravone results in increased phosphorylation of MAPK8 protein Edaravone results in decreased phosphorylation of MAPK8 protein |
CTD |
PMID:15824197 PMID:19954754 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
EXP |
Edaravone results in decreased expression of MMP2 protein Edaravone inhibits the reaction [Paraquat results in increased expression of MMP2 mRNA] |
CTD |
PMID:19381132 PMID:21040696 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [PLAT protein results in increased expression of and results in increased activity of MMP9 protein]; Edaravone inhibits the reaction [PLAT protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:19095969 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
affects expression decreases activity multiple interactions decreases expression |
EXP |
Edaravone affects the expression of MPO mRNA Edaravone results in decreased activity of MPO protein Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] Edaravone results in decreased expression of MPO protein |
CTD |
PMID:14654979 PMID:18031376 PMID:19694712 PMID:20035747 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NCF1 mRNA] |
CTD |
PMID:18643790 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Rotenone results in decreased expression of NDUFS1 mRNA] |
CTD |
PMID:27108097 |
|
NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Rotenone results in decreased expression of NDUFS4 mRNA] |
CTD |
PMID:27108097 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO EXP |
Edaravone affects the localization of NFE2L2 protein [Edaravone co-treated with Chlorpyrifos] results in increased expression of NFE2L2 protein; Edaravone promotes the reaction [Carbon Monoxide results in increased expression of NFE2L2 protein] |
CTD |
PMID:25348283 PMID:25422538 PMID:30758894 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
EXP |
Edaravone results in increased expression of NFKBIA mRNA |
CTD |
PMID:18078833 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
increases expression multiple interactions |
ISO |
Edaravone results in increased expression of NGF mRNA; Edaravone results in increased expression of NGF protein pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF mRNA]; pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF protein]; U 0126 inhibits the reaction [Edaravone results in increased expression of NGF mRNA]; U 0126 inhibits the reaction [Edaravone results in increased expression of NGF protein] |
CTD |
PMID:19954754 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Pilocarpine results in increased expression of NOS1 protein] |
CTD |
PMID:18672383 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases degradation decreases expression |
ISO EXP |
Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] Edaravone results in increased degradation of NOS2 mRNA Edaravone results in decreased expression of NOS2 protein Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Edaravone inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Edaravone inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein] |
CTD |
PMID:15629513 PMID:18078833 PMID:18496239 PMID:18672383 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression decreases degradation |
EXP ISO |
Edaravone results in increased expression of NOS3 mRNA; Edaravone results in increased expression of NOS3 protein Edaravone results in decreased degradation of NOS3 mRNA |
CTD |
PMID:12969758 PMID:15721014 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Edaravone results in decreased expression of NPPA mRNA |
CTD |
PMID:15824197 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Edaravone analog results in increased cleavage of PARP1 protein |
CTD |
PMID:25684395 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pepd |
peptidase D |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Valproic Acid results in increased activity of PEPD protein] |
CTD |
PMID:34309930 |
|
NCBI chr 1:87,536,650...87,681,233
Ensembl chr 1:87,536,609...87,681,231
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
EXP |
Edaravone inhibits the reaction [PLAT protein results in increased activity of RELA protein]; Edaravone inhibits the reaction [PLAT protein results in increased expression of and results in increased activity of MMP9 protein]; Edaravone inhibits the reaction [PLAT protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:19095969 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Valproic Acid results in decreased activity of PON1 protein] |
CTD |
PMID:34309930 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Rotenone results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:30240821 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prnp |
prion protein |
multiple interactions |
EXP |
Edaravone inhibits the reaction [PRNP protein alternative form results in decreased activity of SOD1 protein]; Edaravone inhibits the reaction [PRNP protein alternative form results in decreased activity of SOD2 protein]; Edaravone inhibits the reaction [PRNP protein alternative form results in increased activity of CASP3 protein] |
CTD |
PMID:20806394 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
EXP ISO |
Edaravone inhibits the reaction [IL1B protein results in increased localization of and results in increased activity of RELA protein]; Edaravone inhibits the reaction [PLAT protein results in increased activity of RELA protein] Edaravone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] Edaravone results in decreased expression of RELA protein |
CTD |
PMID:18078833 PMID:19095969 PMID:19381132 PMID:36343683 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [SDC2 protein promotes the reaction [Oxygen deficiency results in increased abundance of Reactive Oxygen Species]]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of CCL2 protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of CXCL12 protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of IL1B protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of TNF protein] |
CTD |
PMID:18803305 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sele |
selectin E |
decreases expression |
EXP |
Edaravone results in decreased expression of SELE mRNA; Edaravone results in decreased expression of SELE protein |
CTD |
PMID:17064733 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Slc6a15 |
solute carrier family 6 member 15 |
multiple interactions |
ISO |
Edaravone inhibits the reaction [Corticosterone results in decreased expression of SLC6A15 mRNA] |
CTD |
PMID:31344373 |
|
NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [PRNP protein alternative form results in decreased activity of SOD1 protein] |
CTD |
PMID:20806394 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [PRNP protein alternative form results in decreased activity of SOD2 protein] |
CTD |
PMID:20806394 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:21040696 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Rotenone results in decreased expression of TH protein] |
CTD |
PMID:27108097 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Paraquat results in increased expression of TIMP1 mRNA] |
CTD |
PMID:21040696 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
Edaravone inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Edaravone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased secretion of TNF protein]; Edaravone inhibits the reaction [Paraquat results in increased expression of TNF protein]; Edaravone inhibits the reaction [SDC2 protein results in increased expression of and results in increased secretion of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA] Edaravone inhibits the reaction [Thioacetamide results in increased expression of TNF mRNA] Edaravone results in decreased expression of TNF mRNA; Edaravone results in decreased expression of TNF protein |
CTD |
PMID:12954792 PMID:14567445 PMID:15629513 PMID:15948865 PMID:17064733 PMID:18803305 PMID:20035747 PMID:21040696 PMID:36343683 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Isoproterenol results in increased expression of UCP2 mRNA]; Edaravone inhibits the reaction [Isoproterenol results in increased expression of UCP2 protein] |
CTD |
PMID:16580698 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
EXP |
Edaravone results in decreased expression of VCAM1 protein |
CTD |
PMID:19381132 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[Edaravone inhibits the reaction [HIF1A protein binds to VEGFA promoter]] which affects the expression of VEGFA mRNA; Edaravone inhibits the reaction [HIF1A protein binds to VEGFA promoter]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; Edaravone inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] |
CTD |
PMID:17889387 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wdr35 |
WD repeat domain 35 |
multiple interactions |
EXP |
Edaravone inhibits the reaction [domoic acid results in increased expression of WDR35 protein] |
CTD |
PMID:23289926 |
|
NCBI chr 6:31,771,315...31,831,450
Ensembl chr 6:31,771,360...31,831,029
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
Edaravone inhibits the reaction [Valproic Acid results in increased activity of XDH protein] |
CTD |
PMID:34309930 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|